Immunocore (NASDAQ:IMCR) Stock Rating Reaffirmed as “Buy” by HC Wainwright

Immunocore (NASDAQ:IMCR – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $100.00 price objective on the stock. HC Wainwright‘s price objective points to a potential upside of 215.71% from the company’s previous close.

A number of other analysts have also recently commented on IMCR. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, October 15th. Mizuho upped their price objective on Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research report on Monday, July 13th. TD Cowen raised Immunocore to a “strong-buy” rating in a research report on Monday, August 24th. Finally, JPMorgan Chase & Co. started coverage on Immunocore in a research report on Friday, August 21st. They issued an “overweight” rating and a $50.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $56.38.

View Our Latest Stock Report on Immunocore

Immunocore Stock Down 0.9%

NASDAQ IMCR opened at $31.68 on Monday. Immunocore has a twelve month low of $27.50 and a twelve month high of $40.71. The stock’s 50-day simple moving average is $32.66 and its two-hundred day simple moving average is $31.83. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of -85.61 and a beta of 0.81.

Immunocore (NASDAQ:IMCR – Get Free Report) last released its earnings results on Friday, August 7th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). On average, equities analysts expect that Immunocore will post 0.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunocore

Institutional investors have recently bought and sold shares of the business. Engineers Gate Manager LP lifted its position in shares of Immunocore by 334.3% in the second quarter. Engineers Gate Manager LP now owns 60,327 shares of the company’s stock worth $1,915,000 after buying an additional 46,435 shares in the last quarter. Braidwell LP bought a new position in Immunocore during the second quarter valued at approximately $16,552,000. Eversept Partners LP bought a new position in Immunocore during the first quarter valued at approximately $1,183,000. Public Employees Retirement System of Ohio bought a new position in Immunocore during the second quarter valued at approximately $2,145,000. Finally, Stempoint Capital LP bought a new position in Immunocore during the first quarter valued at approximately $1,916,000. Hedge funds and other institutional investors own 84.50% of the company’s stock.

About Immunocore

(Get Free Report)

Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.

The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.

See Also

Analyst Recommendations for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.